Fast Locator 2011-2012: PharmaCore, Inc. - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: PharmaCore, Inc.

Since 2000, PharmaCore has performed a variety of chemistry services for leading pharmaceutical and biotechnology companies including: custom organic synthesis; cGMP scale-up; development of novel molecular building blocks; chemical process research and development; and medicinal chemistry services.

Custom Organic Synthesis
Custom organic synthesis is one of the things PharmaCore does best.

PharmaCore’s chemists can synthesize new compounds rapidly, keeping your research on track. For the large pharmaceutical company, that means supplementing your world-class research programs. For smaller companies, PharmaCore can serve as your off-site “chemistry department.”

With increasing dependence of the industry on outsourcing synthetic chemistry, large pharmaceutical companies and emerging drug discovery companies come to PharmaCore to turn multiple synthesis steps with marginal yields into practical chemistry with higher yields.

GMP Manufacturing
PharmaCore has developed an outstanding state-of-the-art facility to serve the growing need for GMP clinical material and bulk active pharmaceutical ingredients (APIs) accompanying the rapid pace of drug discovery.

PharmaCore's new GMP manufacturing facility features five new production suites. The plant is designed with maximum versatility with process conditions of -70 to 160+°, glass and Hastelloy, computer monitoring and flexible equipment configurations. Reactors with process volumes from 2000 liters to laboratory scale are ready to supply your clinical needs.

GMP Analytical
PharmaCore's new GMP analytical laboratories are equipped with the most up-to-date instrumentation to serve your analytical needs, including ICH Q1A-compliant stability chambers. Our services include: analytical methods development/validation/transfer; analytical methods improvement; ICH stability studies, storage and testing; reference standard qualification; and product release/retain. Our seasoned team of scientists brings a wealth of pharmaceutical industry experience to your project.

Our continued success is due to our competitive pricing, our unwavering commitment to customer service and to the talent and experience of our scientists.

Regions where services are provided:

North America, Europe, Asia (global)

Outsourcing serivces provided:

Development and Phase I/IICTM

  • Process development-small molecule

Commercial Manufacturing

  • API and advanced intermediates (GMP, small molecules)

Analytical Services

  • Chemistry and stability

API Production Technologies

  • Acetylenic chemistry
  • Acid chlorides
  • Acylation
  • Amidation
  • Amino acids and analogs
  • Azide chemistry
  • Borane chemistry
  • Bromine chemistry/bromination
  • Carbohydrate chemistry
  • Heterocyclic chemistry
  • Fluorination
  • Hydrazine chemistry
  • Nitration
  • Organometallic chemistry
  • Phosgenation
  • Sulfonation



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here